Cargando…

Lung Cancer Screening: New Perspective and Challenges in Europe

SIMPLE SUMMARY: Screening for lung cancer in a high-risk population has been shown to be beneficial, with reduced mortality in large randomised trials. However, the general implementation of screening is not evident and many factors have to be considered. In this paper, we will review the current st...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Meerbeeck, Jan P., O’Dowd, Emma, Ward, Brian, Van Schil, Paul, Snoeckx, Annemiek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099920/
https://www.ncbi.nlm.nih.gov/pubmed/35565472
http://dx.doi.org/10.3390/cancers14092343
_version_ 1784706725639618560
author Van Meerbeeck, Jan P.
O’Dowd, Emma
Ward, Brian
Van Schil, Paul
Snoeckx, Annemiek
author_facet Van Meerbeeck, Jan P.
O’Dowd, Emma
Ward, Brian
Van Schil, Paul
Snoeckx, Annemiek
author_sort Van Meerbeeck, Jan P.
collection PubMed
description SIMPLE SUMMARY: Screening for lung cancer in a high-risk population has been shown to be beneficial, with reduced mortality in large randomised trials. However, the general implementation of screening is not evident and many factors have to be considered. In this paper, we will review the current status of screening for lung cancer in Europe and the many hurdles that have to be overcome. Multidisciplinary cooperation between all specialists dealing with lung cancer is required to obtain the best outcome. Hopefully, Europe’s Beating Cancer Plan will incorporate screening for lung cancer to allow general implementation by similar programmes in every European Member State. This will also provide an opportunity for further, large-scale studies to refine the inclusion of specific risk populations, diagnosis and management of screen-detected nodules. ABSTRACT: Randomized-controlled trials have shown clear evidence that lung cancer screening with low-dose CT in a high-risk population of current or former smokers can significantly reduce lung-cancer-specific mortality by an inversion of stage distribution at diagnosis. This paper will review areas in which there is good or emerging evidence and areas which still require investment, research or represent implementation challenges. The implementation of population-based lung cancer screening in Europe is variable and fragmented. A number of European countries seem be on the verge of implementing lung cancer screening, mainly through the implementation of studies or trials. The cost and capacity of CT scanners and radiologists are considered to be the main hurdles for future implementation. Actions by the European Commission, related to its published Europe’s Beating Cancer Plan and the proposal to update recommendations on cancer screening, could be an incentive to help speed up its implementation.
format Online
Article
Text
id pubmed-9099920
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90999202022-05-14 Lung Cancer Screening: New Perspective and Challenges in Europe Van Meerbeeck, Jan P. O’Dowd, Emma Ward, Brian Van Schil, Paul Snoeckx, Annemiek Cancers (Basel) Review SIMPLE SUMMARY: Screening for lung cancer in a high-risk population has been shown to be beneficial, with reduced mortality in large randomised trials. However, the general implementation of screening is not evident and many factors have to be considered. In this paper, we will review the current status of screening for lung cancer in Europe and the many hurdles that have to be overcome. Multidisciplinary cooperation between all specialists dealing with lung cancer is required to obtain the best outcome. Hopefully, Europe’s Beating Cancer Plan will incorporate screening for lung cancer to allow general implementation by similar programmes in every European Member State. This will also provide an opportunity for further, large-scale studies to refine the inclusion of specific risk populations, diagnosis and management of screen-detected nodules. ABSTRACT: Randomized-controlled trials have shown clear evidence that lung cancer screening with low-dose CT in a high-risk population of current or former smokers can significantly reduce lung-cancer-specific mortality by an inversion of stage distribution at diagnosis. This paper will review areas in which there is good or emerging evidence and areas which still require investment, research or represent implementation challenges. The implementation of population-based lung cancer screening in Europe is variable and fragmented. A number of European countries seem be on the verge of implementing lung cancer screening, mainly through the implementation of studies or trials. The cost and capacity of CT scanners and radiologists are considered to be the main hurdles for future implementation. Actions by the European Commission, related to its published Europe’s Beating Cancer Plan and the proposal to update recommendations on cancer screening, could be an incentive to help speed up its implementation. MDPI 2022-05-09 /pmc/articles/PMC9099920/ /pubmed/35565472 http://dx.doi.org/10.3390/cancers14092343 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Van Meerbeeck, Jan P.
O’Dowd, Emma
Ward, Brian
Van Schil, Paul
Snoeckx, Annemiek
Lung Cancer Screening: New Perspective and Challenges in Europe
title Lung Cancer Screening: New Perspective and Challenges in Europe
title_full Lung Cancer Screening: New Perspective and Challenges in Europe
title_fullStr Lung Cancer Screening: New Perspective and Challenges in Europe
title_full_unstemmed Lung Cancer Screening: New Perspective and Challenges in Europe
title_short Lung Cancer Screening: New Perspective and Challenges in Europe
title_sort lung cancer screening: new perspective and challenges in europe
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099920/
https://www.ncbi.nlm.nih.gov/pubmed/35565472
http://dx.doi.org/10.3390/cancers14092343
work_keys_str_mv AT vanmeerbeeckjanp lungcancerscreeningnewperspectiveandchallengesineurope
AT odowdemma lungcancerscreeningnewperspectiveandchallengesineurope
AT wardbrian lungcancerscreeningnewperspectiveandchallengesineurope
AT vanschilpaul lungcancerscreeningnewperspectiveandchallengesineurope
AT snoeckxannemiek lungcancerscreeningnewperspectiveandchallengesineurope